Influence of trazodone on the pharmacodynamics and pharmacokinetics of pioglitazone. 2022

Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (Autonomous), Anantapur, Andhra Pradesh, India.

These days, poly pharmacy is very common for the treatment of multiple diseases and majority of drugs were metabolized with CYP 450 enzymes. Diabetes mellitus is such a disorder, which requires continuous therapy for the control of blood glucose concentration. Depression was quite common in diabetic patients. Therefore, multiple drugs required to treat diabetes mellitus and depression. Simultaneous administration of these drugs leads to drug interaction. Pioglitazone and trazodone metabolized by CYP3A4 enzymes which may lead to potential drug interaction. This study aimed to find the influence of trazodone on the pharmacokinetics & pharmacodynamics of pioglitazone in normal & diabetic rats, also on rabbits and subsequently effectiveness and safety of the combination was evaluated. Blood glucose concentration was determined by Glucose oxidase/peroxidase method in normal and diabetic rats. Diabetes was induced with Streptozotocin at a dose of 55 mg/kg body weight. Serum pioglitazone concentration was estimated by high performance liquid chromatography method for pharmacokinetic data. The values were expressed as Mean ± Standard Error Mean (SEM), GraphPad Prism 3.0 (San Diego, California, USA) software was used to express the data. Student's paired 't' test was used to determine the significance. Pioglitazone produces hypoglycaemia in normal rats with a maximum decrease of 36.78 % ± 0.81 at 3 hours interval and anti-hyperglycaemic activity in diabetic rats with maximum reduction of 45.13 % ± 1.52 at 2 hours interval. Trazodone altered the pharmacokinetics of pioglitazone and improved the pioglitazone hypoglycaemic effect. Trazodone apparently produced pharmacokinetic interaction with pioglitazone which might be by attenuating the metabolism of pioglitazone. Therefore, care should be taken in simultaneous therapy with pioglitazone and trazodone.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014196 Trazodone A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) AF-1161,Apo-Trazodone,Deprax,Desyrel,Gen-Trazodone,Molipaxin,Novo-Trazodone,Nu-Trazodone,PMS-Trazodone,Ratio-Trazodone,Thombran,Tradozone,Trazodon Hexal,Trazodon-Neuraxpharm,Trazodone Hydrochloride,Trazon,Trittico,AF 1161,AF1161,Apo Trazodone,Gen Trazodone,Novo Trazodone,Nu Trazodone,PMS Trazodone,Ratio Trazodone,RatioTrazodone,Trazodon Neuraxpharm,TrazodonNeuraxpharm
D045162 Thiazolidinediones THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). Glitazones

Related Publications

Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
January 2017, Current clinical pharmacology,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
January 2019, Journal of pharmacological sciences,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
November 2017, Pharmacogenomics,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
August 2020, Pharmaceutics,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
March 1993, Clinical pharmacology and therapeutics,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
November 1998, International journal of clinical pharmacology and therapeutics,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
January 1976, Archivum immunologiae et therapiae experimentalis,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
October 1988, Clinical pharmacology and therapeutics,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
January 1982, Arzneimittel-Forschung,
Bhupalam Pradeepkumar, and Narayana Goruntla, and Haranath Chinthaginjala, and K Somasekhar Reddy, and Abdul Ahad, and A Sudheer, and M Raghavendra
January 1977, Archivum immunologiae et therapiae experimentalis,
Copied contents to your clipboard!